NEWS: New Targeted Breast Cancer Drug Approved in UK

As reported by the National Health Executive, a new medicine has been cleared for use in the UK, offering an additional option for certain patients with advanced breast cancer whose disease has progressed despite hormone therapy

The drug, imlunestrant tosylate, marketed as Inluriyo, is designed for adults with locally advanced or metastatic cancer linked to ESR1 gene mutations. These mutations can enable tumours to evade the effects of conventional endocrine treatments, limiting effective options once resistance develops.

The Medicines and Healthcare products Regulatory Agency (MHRA) said the treatment is approved for patients who have already received at least one line of hormonal therapy.

Eligibility for the drug depends on three clinical factors:

• An ESR1 mutation must be present

• The cancer must be oestrogen receptor positive
• The tumour must test HER2 negative

The authorisation means clinicians can now consider this targeted therapy for patients with ER positive, HER2 negative disease whose cancer is no longer controlled by standard hormone-based approaches.

As with all medicines granted approval in the UK, the MHRA will continue to oversee its safety and effectiveness as it becomes established in clinical practice.